

Current Position

- Associate Professor of Medicine
- Clinical Director of Lymphoma Services
- Morton and Sandra Saffer Endowed Chair in Hematology Research.
- Division of Hematology
- Department of Medicine
- University of Colorado School of Medicine

Education and Post Graduate Training

2013 - 2014 **Stanford University**, Stanford, CA
Fellowship Division of Blood and Marrow Transplantation

2010 - 2013 **East Carolina University (ECU)**, Greenville, NC
Fellowship Department of Hematology and Oncology, Vidant Medical Center

2007 - 2010 **East Carolina University**, Greenville, NC
Residency Department of Internal Medicine, Vidant Medical Center

1999 - 2004 **K.J. Somaiya Medical College**, Mumbai, India

Medical School MBBS - Bachelor of Medicine and Bachelor of Surgery

Academic Appointments

7/2020-Present Associate Professor, University of Colorado School of Medicine, Division of Hematology, Blood Cancer and Bone Marrow Transplantation Program

11/2014-Current Clinical Director of Lymphoma Services

11/2014-6/2020 Assistant Professor, University of Colorado School of Medicine, Division of Hematology, Blood Cancer and Bone Marrow Transplantation Program

Professional Positions, Organizations and Committees**Institutional**

2022-present Co-Director Disease State CAR-T cell therapy Committee – Division of Hematology
2019-present University of Colorado Immunotherapy lead for lymphomas
2017-2023. Hematology/Oncology Fellowship selection committee
2017-present University of Colorado Pharmacy and therapeutics committee Member and
Lymphoma lead
2014-present University of Colorado Clinical Director of Lymphoma Services
2012 – 2013 Chief Fellow Dept. of Hematology and Oncology East Carolina University
2008 – 2010 Residency Recruitment Committee at East Carolina University

Regional/National

2025 Co-Chair for the LRF CAR-T cell therapy Summit

2023-2025 Highlights of American Society of Hematology (ASH) Program Committee Member

2024 Course Director for the Denver American Society of Hematology (ASH) review

2024 Co-Chair of the Lymphoma Research Foundation (LRF) Spring virtual workshop

2023 Chair of ASH Education session entitled "How do we calibrate cellular therapy in relapsed lymphomas in 2023?"

2023 Faculty member of the LRF's Lymphoma Scientific Research Mentoring Program (LSRMP)

2023-2024 ASH Education Program Committee Member

2023-present Southwest Oncology Group (SWOG) Champion for Intergroup Study ANHL1931

2017-present National Comprehensive Cancer Network (NCCN), CLL/SLL/Hairy Cell Leukemia Committee Member

2015-present SWOG, Lymphoma Committee Member

Honors, Special Recognitions and Awards

2025 Inaugural member of the School of Medicine's Faculty Philanthropic Cabinet.

2024-present Morton and Sandra Saffer Endowed Chair in Hematology Research

2023 Recipient of the inaugural University of Colorado School of Medicine Distinguished Physician Award.

2022 Outstanding Innovator, Division of Hematology

2020 Outstanding Clinical Leader, Division of Hematology

2019 -21 LRF Scholar for the lymphoma scientific research clinical mentoring program (LSRMP)

2017 Featured MD in the annual impact journal *Momentum*

2016 Featured MD in the C3 (Collaborating to Conquer Cancer) Magazine

2015 Leadership and Service award; Division of Hematology, University of Colorado

2011 Outstanding presenter of the year in the trainee category at Research Day, ECU

2009 – 2010 Eugene Furth, MD award for Outstanding Senior Resident in Medicine, ECU

2009-2010 Outstanding resident in Ambulatory General Medicine, ECU

2009 – 2010 Sir William Osler award for Outstanding Cardiology Resident, ECU

2007 – 2008 Medicine Intern of the year, ECU

2007 -2008 Hematology-Oncology Intern of the year, ECU

1999 – 2004 Sir J.R.D. Tata Scholarship (partly funded medical school)

2004 Gold Medal State award in Pediatrics, Mumbai University, India

1999 – 2004 Distinction in Pharmacology, Microbiology, General Surgery and Ophthalmology

Licensure and Certifications

Board certified in Internal Medicine 2010, recertification in 2020
Board certified in Hematology 2013, Enrolled in Longitudinal Assessment for recertification
Board certified in Oncology 2013, Enrolled in Longitudinal Assessment for recertification
Colorado state medical license (2014)
Wyoming state medical license (2021)
ECFMG certified (2007)
Indian Medical License (2005)
National Provider Number 1184817959
State and Federal controlled substance licenses

Review and Referee Work

2025 Leukemia Lymphoma Society Grant Reviewer Committee member for Scholar in Clinical Research
2020-2025 Data Safety Monitoring Committee member for clinical protocol – “Magnify: Phase 3b Study of Lenalidomide + Rituximab (R²) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma”
2024 American Society of Hematology Annual Meeting Oral Session Moderator for Section 906: Outcomes research- Driving CARs home
2022 American Society of Hematology Annual Meeting Oral Session Moderator for Section 623. Mantle Cell, Follicular Lymphomas: Clinical and Epidemiological
2022 Session Chair for Aggressive B-Cell Lymphoma for Society of Hematology Oncology (SOHO) Congress
2021-pre. Data Safety Monitoring Committee member for clinical protocol “CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy.”
2021 American Society of Hematology Annual Meeting Oral session Moderator for Section 704. Cellular Immunotherapies: Expanding Targets and Cellular Sources for Immunotherapy
2019 American Society of Clinical Oncology Poster discussion session Moderator for section: Hematologic Malignancies-Lymphoma and CLL
2019 Lymphoma Research Foundation (LRF) Grant Reviewer - Fall SAB meeting for clinical research scholar award

Journal Reviewer at Large

2026 Clinical and Translational Medicine
2025 Blood Immunology & Cellular Therapy
2025 Hemisphere
2025 Hematological Oncology
2025 Leukemia
2024-present Blood Neoplasia
2024-present British Journal of Hematology
2023 Journal of Immunotherapy of cancer
2023-present Blood
2023 Cancer
2023-present The Lancet

2022-present European Journal of Haematology
2021-present Blood Advances
2020-present Hematology, the ASH Education Program
2021-present Lancet Haematology
2021-present Leukemia and Lymphoma
2021 Transplantation and Cellular Therapy
2019-present Hematologica
2019 American Journal of Hematology
2017-present Journal of Clinical Oncology
2017-present Journal of Clinical Lymphoma Myeloma and Leukemia
2015-present Journal of the National Comprehensive Cancer Network

Invited Lectures and Presentations**Institutional**

2025 CART cell therapy in Lymphoma-How far have we come?- John Gates Seminar Series
2025 Overview of clinical trials in lymphoma Lunch and Learn with Clinical Trials Unit, Division of Hematology
2025 Management of DLBCL in 2025 Hem-Onc fellows educational conference
2024 Harnessing CD20 BITEs: A New Frontier in NHL Treatment Hem-Onc Grand rounds
2024 Building your own mentorship network Women in Leadership Seminar
2024 Management of DLBCL in 2024 Hem-Onc Grand rounds
2023 Therapy options for DLBCL Radiation/Onc fellows conference
2023 Management of Post-CART cell therapy relapse Hematology Grand rounds
2023 Management of DLBCL in 2023 Hem-Onc fellows educational conference
2023 Clinical Trials in B cell Lymphoma Clinical Trials Unit, Lunch and Learn
2022 Management of DLBCL in 2022 Hematology Grand Rounds
2022 Immunotherapy in lymphomas- The Present and the Future Department Of Medicine Grand Rounds
2022 Cell therapy trials at CU cancer center CART summit 2022
2022 Systemic therapy for lymphoma Rad-Onc grand rounds
2022 CAR-T cell lymphoma in lymphomas Hem-Onc fellows educational conference
2022 State of lymphoma management Cardio-Oncology Academic day
2022 Pearls in lymphoid malignancies Internal Medicine House Staff Education Series
2022 Checkpoint inhibition in B-Cell lymphomas MS Immunology Course IDPT8055
2021 Systemic therapy in DLBCL Rad/Onc grand rounds
2021 New drug approvals in lymphoma in 2020 Hem/Onc grand rounds
2021 Mantle Cell Lymphoma – Review and Updates BMT and Hem grand rounds
2021 Overview of Lymphoma with focus on DLBCL Hem/Onc grand rounds
2021 Checkpoint inhibition in B-Cell lymphomas MS Immunology Course IDPT8055
2020 Clinical Trials Operations BMT/Hem Onc grand rounds
2020 CAR-T cell therapy The Present and the Future. HI3 Immunology case study seminar
2020 Updates in Hodgkin and DLBCL-2020 Rad Onc Grand Rounds
2020 Updates in CLL-2020 Hem Onc Grand Rounds
2020 The coming of age of immunotherapy in B-cell lymphomas Cancer Center Symposium

Manali Kamdar, MD

720-848-0752 (O); 720-848-1786 (F)

Mail Stop F754, Rm 4323, 1665 Aurora Court Aurora, Colorado 80045

manali.kamdar@cuanschutz.edu

2019	Hodgkin Lymphoma : Updates in 2019	BMT and Hem Onc Grand Rounds
2019	CART and PD-1 inhibitor therapy updates	BMT and Hem Onc Grand Rounds
2019	Immunotherapy updates in lymphoma. Fellow recruitment lecture	
2019	State of CLL in 2019	BMT grand rounds and Hem Onc grand rounds
2019	Transformed Lymphoma	BMT Grand rounds and Hem Onc Grand Rounds
2018	How I treat CLL	Hem Onc grand rounds
2018	ASH update in B cell lymphomas	Hem Onc grand rounds
2018	PD-1-PD-L1 checkpoint blockade in lymphomas	BMT grand rounds
2018	Lymphoma: Overview	Breakfast BIC (Blood Cancer infusion Center) talk
2018	Clinical Trials in Lymphoma	HCTU Lunch Talk
2017	Lymphomas: update on radiation therapy use	Rad/Onc grand rounds
2017	Updates in Mantle cell lymphoma	BMT grand rounds
2017	Hodgkin Lymphoma in 2017: Updates	Hem/Onc Grand Rounds
2017	Update on Marginal Zone Lymphoma	BMT AND, Hem/Onc Grand Rounds
2016	Lymphomas: Overview and Updates	APP Oncology Boot Camp
2016	Hodgkin Lymphoma in 2016	Rad/Onc Grand Rounds
2016	Hodgkin Lymphoma	Hem/Onc Grand Rounds
2016	Updates in Lymphomas	Breakfast BIC talk
2016	Roadmap forward in DLBCL	Research and Innovation Conference
2015	ASH 2015 Update (Lymphomas)	Hem/Onc Fellows Conference
2015	Lymphomas (DLBCL,FL,MCL, Burkitt L)	BMT Grand Rounds
2015	Review of Lymphomas	Radiation Oncology Grand Rounds
2015	Overview of Lymphoid malignancies	Clinical Trials Team "Lunch and Learn"
2015	Lymphomas (DLBCL,FL)	Hem/Onc Fellows Conference

Regional

2025	Management of DLBCL in 2025	Refined Biosciences, CU Innovations
2025	State of hematologic malignancies	Community advisory council, Denver
2025	Treatment Sequencing of BTK Inhibitors in R/R CLL/SLL	Onc Live Summit, Denver
2025	Updates in Lymphoma	Highlights of ASH, Denver
2024	CAR-T cell therapy vs Bispecific Antibody Rx	Kaiser hematology Grand Rounds
2022	CART cell therapy – The Present and the Future	RMCC Symposium 2022, CSprings
2022	Invited Panelists for the CU Boulder "Red for Research" Campaign	
2022	CART cell therapy in lymphomas	Robert Allen Hematology Symposia
2020	Best of ASH 2019-Updates in lymphoma	UCH, Colorado update 2020
2019	Ask the Doctor: Updates in lymphomas	Lymphoma research foundation
2019	Best of ASCO 2019- lymphoma	ASCO Direct™ Highlights Denver
2019	Immunotherapy in Lymphomas	UCH Outreach at RMCC, Colorado Springs
2018	Ask the Doctor: B-cell lymphomas	Lymphoma Research Foundation
2018	Echelon-1 overview (Pharma)	Oncology Nursing Association, Denver
2017	Ask the Doctor: Updates in Lymphoma	Lymphoma Research Foundation
2017	Highlights of ASH: B cell Lymphoma	Denver Metro Region
2016	Brentuximab in Lymphomas (Pharma)	Callaway Young Regional Cancer Center
2016	Brentuximab in Lymphomas (Pharma)	Cheyenne Regional Cancer Center
2016	Lymphoma Overview and Updates:	Celgene Educational Denver Region talk
2016	Ask the Doctor: Updates in B cell Lymphoma	Lymphoma Research Foundation
2016	Overview of Brentuximab (Pharma)	Oncology Nursing Association, Denver

2016 ASH Review: Update on Lymphoma UC Health Annual ASH Update CO Springs

National

2026 Highlights of ASH in Aggressive Lymphomas Highlights of ASH (Seattle, WA)
2026 Expanding Access of CAR-T in the community SOHO, Brown Bag Series
2025 Relapsed/Refractory Aggressive NHL LRF, Patient Education National Forum
2025 Cancer Q&A: Understanding the Role and Reality of CAR (Chimeric Antigen Receptor)
T-Cell Therapy for Non-Hodgkin Lymphoma Research To Practice Think Tank
2025 MT-601- Safety and efficacy in Relapsed Lymphomas- 4th Bermuda Translational
Summit on Hematologic Malignancies
2025 Golcadamide in relapsed/refractory follicular lymphoma- 4th Bermuda Translational
Summit on Hematologic Malignancies
2025 UCD 19/22 Bicistronic CAR-T cell therapy for Relapsed Lymphoma- 4th Bermuda
Translational Summit on Hematologic Malignancies
2025 Understanding the Current Paradigm and treatment in NHL Oncology Nursing
Society Congress, RTP session
2025 Highlights of ASH in Aggressive Lymphomas- Highlights of ASH (Washington, DC)
2025 CAR-T cell therapy in R/R Large B cell lymphoma – Research To Practice Think Tank
2024 Treatment Crossroads perspectives on relapsed FL/DLBCL- ASH '24 Satellite Symposium
2024 CAR-T cell therapy in DLBCL- evolving landscape East Carolina University,
Hematology Conference, Key Note Speaker
2024 New diagnosis of Lymphoma Lymphoma Research Foundation Spring Virtual
Workshop (Co-Chair)
2024 ASH Updates in B-cell lymphomas Denver ASH review
2023 Selection of Bispecific Antibody therapies or CAR T-cell therapy in relapsed lymphomas-
ASH Education Program (Chair)
2023 Management of Transformed Lymphomas: LRF North American Educational Forum
2023 Managing Relapsed DLBCL Post CAR-T Therapy: MD Anderson Lymphoma Grand rounds
2023 Update on CAR T-Cell Therapy LRF National Webinar
2023 Therapeutic options for patients with high risk R/R DLBCL ASCO Education Program
2023 Building your mentorship network LSRMP workshop, LRF
2023 National Ask the doc about lymphoma LRF webinar
2022 ASH Post-Conference Perspectives in DLBCL OncLive
2022 DEBATE: How should a patient with R/R DLBCL and PR be treated LLM Congress 2022
2022 Immunotherapy: Beyond CAR-T cell therapy LRF North American Education Forum
2022 DEBATE: CAR T-cell or Auto HDT in relapsed DLBCL SOHO 2022
2022 When to Choose CAR T-cell therapy versus ASCT in R/R DLBCL SOHO 2022
2022 Southwest Lymphoma research Foundation Workshop Co-Chair and Speaker
2022 ASH 2021 Updates in DLBCL SWOG Lymphoma Meeting
2022 Lymphoma Updates Highlights Of ASH 2022
2022 Lymphoma CAR-T cell therapy updates Guest Speaker at UAB Best of ASH Review
2022 National Ask the doc about lymphoma Lymphoma research foundation webinar
2021 Podium to Practice: Data Updates from the 2021 Annual Hematology Meeting
University of Nebraska and Bioascend.
2021 Narrowing the gaps in MZL treatment – targeting BTK and PI3K LLM Congress
2021 Transformed Marginal Zone lymphoma LRF Transformed Lymphomas Workshop

2021	Best of ASCO 2021- lymphoma	ASCO Direct™ Highlights Denver
2021	How to approach MZL/WM	Great Debates and Updates in Hematologic Malignancies
2021	Updates in the treatment of Mantle Cell Lymphoma	<i>OncLive®</i> workshop
2020	Best of ASCO 2020- lymphoma	ASCO Direct™ Highlights Denver
2020	Imaging and Scans: Why do I need it.	North American Educational Forum (LRF)
2020	Marginal zone lymphoma-Update	Lymphoma Research Foundation Webinar
2019	Updates in Marginal Zone lymphoma	North American Educational Forum (LRF)
2019	Brentuximab in lymphomas	Santa Fe, NM Cancer Center
2019	Immunotherapy in lymphoma	Plenary Session: Arizona lymphoma workshop
2019	DLBCL/Burkitt lymphoma	Arizona lymphoma workshop (LRF)
2018	Marginal Zone lymphoma	North American Educational Forum (LRF)
2018	Mantle cell lymphoma	Arizona lymphoma workshop
2017	Mantle cell lymphoma	AZD National educational program
2017	ASH 2016: Highlights in B cell lymphoma, University of Oklahoma, Grand Rounds	
2016	ASH 2015: Highlights in lymphoid malignancy, East Carolina University, NC,	

International

2025	Second-Line Management of LBCL in 2025	ASH'25, Japan Hematology Group
2025	All CAR-Ts are not the same-DLBCL/FL Trials	Mumbai, India Hematology Webinar
2025	Highlights of EHA and ICML in DLBCL/FL/MCL Post-Summer Congress Training Webinar	
2025	EHA and ICML Updates in Hodgkin Lymphoma	EPICS conference Aptitude Health
2025	Optimizing patient and CAR T selection for R/R FL	European Hematology Association (EHA) Congress, Satellite Symposium
2025	Managing LBCL in the Second Line with CAR-T	International Congress for Malignant Lymphoma Congress, Switzerland, Satellite Symposium
2025	Advancing CAR-T for LBCL Bridging the Gap to Cure	European Hematology Association (EHA) Congress, Satellite Symposium
2025	How I use CD19-CAR-T cell therapy in Follicular Lymphoma	BMS FL Education session
2025	Evolving Paradigms in the First Relapse DLBCL – Women In Lymphoma podcast	
2024	CAR-T cell therapy in Relapsed LBCL	BMS Practice Exchange, Japan
2024	Updates in Aggressive Lymphomas	Highlights of ASH (Dubai, UAE)
2023	Lymphoma Diagnosis & Management	MedALL Webinar
2023	CAR-T in Relapsed DLBCL:State of the Art 10 th Whistler Summit Hem Malignancies	
2023	Tackling post-CART therapy relapse	10 th Whistler Summit Hem Malignancies
2023	Post-ASH Data International Workshop on Non-Hodgkin lymphoma (iwNHL)	
2022	DEBATE: Is CART cell therapy one size fits all for high risk R/R DLBCL	COLYM 2022
2022	Meet the CAR-T Expert (Virtual)	Practice Exchange, Spain
2022	Lymphoma Educational Series	AZD, Meet the Experts
2022	How does the world stand up to cellular therapies- US perspective	Women In Lymphoma, Webinar
2022	CAR-T cell therapy in DLBCL	Canadian Conference on Lymphoproliferative Disorders
2022	Post-ASH Data -Key takeways - International Workshop on Non-Hodgkin lymphoma (iwNHL)	International Workshop on Non-Hodgkin lymphoma (iwNHL)
2021	Lymphoma updates: 2020 in review	Mumbai, India Hematology Group Webinar

Webinar	2020	Practice changing updates in Lymphomas	Mumbai, India	Hematology Group
	2019	Immunotherapy and CAR therapy in lymphomas	Best of Lugano, Mumbai, India	
	2018	Best of ASH: Update in indolent B cell lymphomas	41 st Mumbai hematology Meeting	
	2018	PD1/PDL1 checkpoint blockade in lymphomas	41 st Mumbai Hematology Meeting	

Media – Interviews/Features

2026 Featured MD in Colorado at 150 years celebration <https://co150film.com/>

2026 Everyday Health stories:<https://www.everydayhealth.com/cancer/how-supportive-care-fits-into-large-b-cell-lymphoma-treatment/>

<https://www.everydayhealth.com/cancer/diet-exercise-during-treatment-for-large-b-cell-lymphoma/>

2025 Led the Trial that helped get FDA approval for Reduced monitoring of Lisocabtagene Maraleucel in relapsed refractory lymphomas
<https://www.businesswire.com/news/home/20250626606677/en/U.S.-Food-and-Drug-Administration-Approves-Streamlined-Patient-Monitoring-Requirements-and-Removal-of-REMS-Programs-within-Bristol-Myers-Squibbs-Cell-Therapy-Labels>

<https://news.cuanschutz.edu/cancer-center/kamdar-hemotology-lymphoma-car-t-cell>

2025 Featured MD in *CU Connections* <https://news.cuanschutz.edu/news-stories/dancer-to-doctor-dreams-fuel-top-lymphoma-researchers-success>

2025 Featured MD in ‘Where Dreams Live’: CU Anschutz Ad Campaign
<https://www.youtube.com/watch?v=2hVRXQW-iyw>

2023 Speaker at the Transforming Health care series at Anschutz Cancer center
<https://news.cuanschutz.edu/news-stories/cu-anschutz-takes-the-reins-in-car-t-cancer-therapy-research>

2023 Medscape- Speaker for Mantle Cell Lymphoma Decision point series
<https://decisionpoint.medscape.com/oncology>

2022 Featured MD in the CU Chancellor’s annual “State of the Campus” address
<https://www.youtube.com/watch?v=jDBy9C6R8GQ>

2022 Featured CAR-T related work in Nature Portfolio: <https://www.nature.com/articles/d42473-022-00262-3>

2022 Featured MD-patient story in UC Health today <https://www.uchealth.org/today/combine-lymphoma-and-crohns-disease-takes-a-village/>

Manali Kamdar, MD

Mail Stop F754, Rm 4323, 1665 Aurora Court Aurora, Colorado 80045

720-848-0752 (O); 720-848-1786 (F)

manali.kamdar@cuanschutz.edu

2022 Co-Hosted podcast with Vice Chancellor of Research at the CU Cancer center-

<https://news.cuanschutz.edu/news-stories/why-is-car-t-cell-therapy-one-of-the-most-phenomenal-advances-in-science>

2022 Featured MD in CU Anschutz cancer center updates <https://news.cuanschutz.edu/news-stories/signature-benefactor-event-shines-spotlight-on-healthcare-honorees>

2022 Featured in the ASCO Post <https://ascopost.com/videos/2021-ash-annual-meeting-exposition/manali-kamdar-on-large-b-cell-lymphoma-lisocabtagene-maraleucel-vs-the-standard-of-care/>

2022 Featured MD in Heilio <https://www.heilio.com/news/hematology-oncology/20220214/cart-poised-to-create-paradigm-shift-in-nonhodgkin-lymphoma>

2021 Led the Trial that helped get FDA approval for Lisocabtagene Maraleucel in relapsed refractory and changed standard of care. Media Clips highlighting work with Lisocabtagene CAR T cell therapy

AJMC: <https://www.ajmc.com/view/liso-cel-offers-breakthrough-in-second-line-treatment-of-lbcl-kamdar-says>

ASH: <https://www.onclive.com/view/liso-cel-significantly-prolongs-efs-over-soc-in-second-line-relapsed-refractory-lbcl>

ASH: <https://www.onclive.com/view/dr-kamdar-on-the-results-of-the-transform-trial-in-relapsed-refractory-lbcl>

ASCO Post: <https://ascopost.com/videos/2021-ash-annual-meeting-exposition/manali-kamdar-on-large-b-cell-lymphoma-lisocabtagene-maraleucel-vs-the-standard-of-care/>

E-Cancer: <https://ecancer.org/en/video/10130-lisocabtagene-maraleucel-demonstrates-improvement-over-standard-of-care-in-2l-lbcl>

2021 Featured MD in CU Anschutz cancer center updates <https://news.cuanschutz.edu/cancer-center/new-hope-for-patients-with-relapsed-large-b-cell-lymphoma>

2021 Featured MD in Chancellor of CU's annual "State of the Campus" address

<https://www.cuanschutz.edu/about/leadership/chancellor/sotc/2021-state-of-the-campus>

2021 Featured MD in CU Anschutz *TODAY* <https://news.cuanschutz.edu/news-stories/more-leadership-roles-for-women-in-healthcare-equals-accelerating-overall-improvement-in-medicine>

2021 Featured MD in CU Cancer updates <https://news.cuanschutz.edu/cancer-center/lymphoma-program-celebrates-six-years>

2021 Featured story in UC Health updates <https://www.uchealth.org/today/family-faith-and-friends-combine-to-turn-back-cancer-and-covid-19/>

Manali Kamdar, MD

Mail Stop F754 1665 Aurora Court Aurora, Colorado 80045

720-848-0752 (O); 720-848-1786 (F)

manali.kamdar@ucdenver.edu

2021 Featured MD in CU Cancer updates <https://news.cuanschutz.edu/news-stories/cancer-patient-sees-total-remission-with-cell-therapy-created-by-cu-anschutz-scientists>

2020 Featured MD LRF Researcher for the [Pulse](https://lymphoma.org/aboutlrf/pulse/) <https://lymphoma.org/aboutlrf/pulse/>

2020 Featured MD in Cu Cancer updates <https://news.cuanschutz.edu/news-stories/living-to-live-friends-face-off-cancer-find-strength-in-each-other>

2020 Featured expert in HemOnc today on biosimilars: <https://www.healio.com/news/hematology-oncology/20201009/greater-uptake-education-needed-to-realize-costsaving-potential-of-biosimilars>

2020 Featured Expert in Lymphoma Research Foundation Facebook Live <https://www.facebook.com/lymphomacommunity/videos/991444594632256/?vh=e&extid=V306PwokMvlpD51A>

2019 DLBCL Outcomes study featured by Medscape <https://www.medscape.com/viewarticle/919875>

2019 Featured MD in Colorado Cancer updates <https://coloradocancerblogs.org/lymphoma-stage-predict-secondary-cancer/>

2018 Update on Mantle Cell Lymphoma : LRF & CancerCare Teleconference https://www.cancercare.org/connect_workshops/692-update_mantle_cell_lymphoma_2018-10-26

2017 CLL society newsletter, *THE CLL tribune* <http://cllsociety.org/2017/09/prognostic-factors-cll/>

2017 Radio interview on Newsradio 850 KOA : Importance of genetic testing in CLL patients

2017 Featured MD in Colorado Cancer blogs <http://www.coloradocancerblogs.org/nejm-case-reports-show-promise-cancer-immunotherapy-treat-rare-lymphoma/>

Teaching Record

Medical Student Lecture Series: MS Immunology Course IDPT 8055 Checkpoint inhibition in B-Cell lymphomas in 2021 and 2022.

Internal Medicine Residency Lecture Series: 2022 -1) Pearls in lymphoid malignancies

2) Internal Medicine Grand Rounds: Immunotherapy in Lymphomas

Hematology/Oncology Fellows Lecture Series: multiple annual presentations 2014 to present

Radiation/Oncology Fellows Lecture Series: multiple presentations from 2016-present

Cardiology Fellows Lecture: Presentation in 2022

Patient Education Talks: multiple bi-annual presentations 2015 to present

Advance Practice Provider Education Talks: multiple annual presentations 2011 to present

Hematology Clinical Trials Staff Education: multiple presentations from 2015-present

BMT Grand Rounds: multiple annual presentations 2015 to present

Ward and Clinic Attending Duties

2014 – Present:

Supervision and bedside teaching of medical students, residents, fellows, nurse practitioners, nurse navigators and physician assistants

4-8 weeks/year inpatient attending wards (30-40 patients on service/day)

Four Half Day Outpatient Clinics per week (~40-50 patients/week)

Self-Improvement

2021-2022 Mid-Career Faculty Women's Leadership Development Program sponsored by the Department of Medicine Program to Advance Gender Equity (PAGE),
2017 Junior Faculty Mentor Program (JUMP) Workshop, University of Colorado, Department of Medicine; focus on developing mentorship skills
2017 Junior Faculty Survival Skills training, University of Colorado
Annual Training: Three-part clinical investigator training course: Regulation and Ethics and Good Clinical Practice

Other Academic Activities/Projects

2025 Outpatient Lymphoma Diagnostics Clinic Development Committee Member, Contributing to the design and implementation of a streamlined clinic to enable faster lymphoma diagnosis and treatment initiation
2025 Search Committee member for next Division Head of Hematology
2023-current Consulting Lymphoma physician for the bi-monthly Kaiser Tumor Board
2017-current Co-Developed an active and running lymphoma database
2015-2024 Chaired weekly tumor board for the Division of Hematology
2016-current Co-developed protocol for tissue banking of lymphoma patients
2015-current Co-Developed Institutional Guidelines for treating Lymphomas
2015-current Co-developed lymphoma cardio oncology program (CCC: Collaborative cardiac care for lymphoma patients) with cardiologist Dr Kondapalli at the University of Colorado

Mentees

Allyson Freedy MD, PhD (MSTP)
Internal medicine resident (2025- present)

Vincent Pizzuti, MD
Internal medicine resident (2024-present)
2025 ASH Honors award Recipient

Megan Connor, MD
Internal medicine resident (2024-present)

Jorge Monge, MD
Assistant Professor at the University of Colorado (2024-present)

Cassandra Duarte, MD
Hem-Onc Fellow (2022-present)- Will onboard as Assistant Professor Starting Sept 2025

Manali Kamdar, MD

Mail Stop F754 1665 Aurora Court Aurora, Colorado 80045

720-848-0752 (O); 720-848-1786 (F)

manali.kamdar@ucdenver.edu

Christopher Alderman

5th year MSTP student (2022- present)

Christine Mcmahon, MD

Assistant Professor at the University of Colorado (2021 – present)

Steven Bair, MD

Assistant Professor at the University of Colorado (2021 – present)

Jodon Gray, MD

Assistant professor at Denver Health (previous fellow at U of Colorado (2020-2023)

Meryl Colton, MD

Internal medicine Chief resident (2020-2023) -Present UCSF Hem/Onc Fellow

Zohra Nooruddin, MD

Past Hematology/Oncology fellow now assistant professor at San Antonio VA

Ajay Major, MD, MBA

Assistant Professor at U of Colorado (Past Resident and Chief Fellow in hematology/oncology at the University of Chicago. (2018-present)

ASH hematology Clinical Research Training Institute (CRTI) member in 2025

Neelam Mistry, MD

Resident in Internal Medicine (2019-2020)

Heather Knowles, PhD, Physician Assistant

Assistant Professor, University of Colorado (2020- 2025)

Now with Industry

Rebecca Hunter, Clinical Psychologist

Assistant Professor, University of Colorado (2020-2022)

Grants and Funding

Active Recipient of seed grant support from the Morton and Sandra Saffer Endowment in Cancer Research

Completed Pilot research fund from Patrick Riley in cancer research

Completed Lymphoma research foundation clinical research program mentoring program. (\$ 10,000 for 2 years)

Awarded Secured funding for Investigator Initiated Trial funding (\$ 50,000) from the Cancer Center for Clinical trial: Ublituximab as initial therapy for treatment-naïve follicular and marginal zone lymphoma with response-driven addition of umbralisib for suboptimal response NCT04508647 (trial is now closed)

Current Clinical Research

Investigator Initiated Clinical Trials: Lead Principal Investigator (PI)

- 1) Phase I Study of Feasibility and Safety of UCD19 CAR-T cells in Adult Subjects with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (Open)
- 2) Phase I/II Study of Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients (Open)
- 3) Molecular disease monitoring and early response/relapse prediction in patients receiving anti-CD19 CAR T cell therapy
- 4) Ublituximab as initial therapy for treatment-naïve follicular and marginal zone lymphoma with response-driven addition of umbralisib for suboptimal response
- 5) Polatuzumab plus Bendamustine plus Rituximab as salvage therapy prior to autologous stem cell transplant for patients with relapsed or primary refractory diffuse large B-cell lymphoma.

Industry Sponsored Clinical Trials (CST):**A. Site Principal Investigator for Presently Open CST Trials**

- 1) A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
- 2) A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma
- 3) SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL) GO44145; NCT06047080
- 4) A Study to Evaluate the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory indolent B-cell Non-hodgkin lymphoma (TRANSCEND FL)
- 5) Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
- 6) Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (APOLLO)

B. Site Principal Investigator for Enrolled and Completed CST Trials

- 1) A Phase IB/II Study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin in combination with rituximab or obinutuzumab plus bendamustine in relapsed or refractory follicular or diffuse large B cell Lymphoma
- 2) A study to compare the efficacy and safety of JCAR017 to Standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell non-hodgkin lymphomas (TRANSFORM) (First Author)
- 3) A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, ACP-196 in Combination With Obinutuzumab, and ACP-196 Monotherapy in Subjects With Previously Untreated CLL

- 4) A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers (Co-PI)
- 5) A study to determine dose, safety, and efficacy of Durvalumab as Monotherapy and in Combination therapy in subjects with Lymphoma or Chronic lymphocytic leukemia
- 6) A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies
- 7) A Study of Idasanutlin in Combination With venetoclax and Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants (Lead International PI)
- 8) Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (Lead PI)
- 9) Study of AZD 5991 in relapsed or refractory haematologic malignancies
- 10) A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma
- 11) Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell non-hodgkin lymphoma (TRANSCEND-NHL-001)

Site Principal Investigator for NCI Co-operative group Clinical Trials (SWOG)

- 1) Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma (S2308)
- 2) A Randomized study of Nivolumab or Brentuximab Vedotin plus AVD in Patients (A>=12 yrs) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma (S1826)
- 3) A Randomized double-blind phase III study of Ibrutinib versus placebo during and following autologous stem cell transplantation in patients with relapsed or refractory diffuse large b cell lymphoma of the activated b-cell subtype
- 4) Obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy in treating patients with relapsed refractory Grade I-IIa follicular lymphoma

Grant Reviewer/Advisor

2025 Grant Reviewer – Leukemia Lymphoma Society (Scholar in Clinical Research)

2022-current Advisory Team Member: K99/R00 grant -PI Zachary Clayton -Translational studies of cellular senescence as a regulator of doxorubicin-mediated arterial dysfunction

2019 Grant Reviewer - Lymphoma Research Foundation (LRF) Fall SAB meeting

Bibliography**Peer Reviewed Manuscripts**

2026 Comparison of Outcomes with Novel vs Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma
Ermann, D, **Kamdar M**, Shah, H et al
Clinical Lymphoma Myeloma Leukemia, DOI: 10.1016/j.clml.2026.01.018

2026 Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma

Manali Kamdar, MD

Mail Stop F754, Rm 4323, 1665 Aurora Court Aurora, Colorado 80045

720-848-0752 (O); 720-848-1786 (F)

manali.kamdar@cuanschutz.edu

Alderucchio J, **Kamdar M**, Cwynarski K et al

Blood 2026; PMID: 41490516 DOI: 10.1182/blood.2025031455

2025 CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting.

Hunter BD, Kamdar M.

Transplant Cell Ther. 2025 Oct 24:S2666-6367(25)01526-X. doi: 10.1016/j.jtct.2025.10.024.

PMID: 41235976

2025 Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.

Hess B, Kamdar M, LaCasce A et al.

Haematologica. 2025 Oct 30. doi: 10.3324/haematol.2025.288232.

PMID: 41163564

2025 Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma.

Sharma S, Kamdar M, Iqbal J; North American Mantle Cell Lymphoma Project (NAMCLP).

Nat Commun. 2025 Nov 5;16(1):9762. doi: 10.1038/s41467-025-64666-7.

PMID: 41193463

2025 Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma.

Abramson JS, Kamdar M, et al

Leuk Lymphoma. 2025 Jul 24:1-14. doi: 10.1080/10428194.2025.2532674.

PMID: 40708270

2025 Who Is Eligible for CAR T-Cell Therapy? Expert Perspectives on Overcoming Referral Barriers

Shadman M, Kamdar M, et al

Transplantation and Cellular Therapy. 2025 Oct

<https://www.sciencedirect.com/science/article/abs/pii/S2666636725015283>

2025 Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-up From the Randomized, Phase III TRANSFORM Study

Kamdar M, Abramson, JS et al

J Clin Oncol. 2025 Jul 7:JCO2500399. doi: 10.1200/JCO-25-00399.

PMID: 40623279

2025 Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study.

Strati P, Kamdar M, Patel K.

Lancet Haematol. 2025 Jul;12(7):e505-e515. doi: 10.1016/S2352-3026(25)00142-5.

PMID: 40610174

2025 Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis

Epstein Z, Kamdar M, Kumar, A et al

Blood Adv 2025:bloodadvances.2025016315. doi: 10.1182/bloodadvances.2025016315

PMID: 40763269

2025 Evopacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study.

Kim TM, **Kamdar M**, Kim WS et al.

Haematologica. 2025 Apr 10. doi: 10.3324/haematol.2024.286208.

PMID: 40207726

2025 Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TN.

Sharman JP, **Kamdar M**, Woyach JA et al

Blood. 2025 Apr 8:blood.2024024476. doi: 10.1182/blood.2024024476.

PMID: 40198878

2025 Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma.

Samples L, **Kamdar M**, Shadman M et al.

Blood. 2025 Feb 12:blood.2024026831. doi: 10.1182/blood.2024026831.

PMID: 39938007

2024 DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell Lymphomas.

Allen J, **Kamdar M**, Major A.

Clin Lymphoma Myeloma Leuk. 2024

PMID: 39426945

2024 CARs to the rescue: rare aggressive lymphoma gets a power up.

Kamdar M.

Blood Adv. 2024 Oct 22;8(20):5342-5343. doi: 10.1182/bloodadvances.2024014118.

PMID: 3939264

2024 High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement and Outcomes in a Multi-Institutional Series.

Epperla N, **Kamdar M**, Olszewski AJ et al

Blood Adv. 2024 Aug 27:bloodadvances.2024013791. doi: 10.1182/bloodadvances.2024013791.

PMID: 39189932

2024 A PHASE 1 FIRST-IN-HUMAN STUDY OF THE MCL-1 INHIBITOR AZD5991 IN PATIENTS WITH RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES.

Desai P, **Kamdar M**, Blachly JS et al

Clin Cancer Res. 2024 Aug 21. doi: 10.1158/1078-0432.CCR-24-0028.

PMID: 39167622

2024 At the Cutting Edge: Novel Agents in Hodgkin Lymphoma and the Evolving Role of Radiation Therapy.

Lo AC, Parikh RR, **Kamdar M**, Milgrom SA.

Int J Radiat Oncol Biol Phys. 2024 Sep 1;120(1):1-9. doi: 10.1016/j.ijrobp.2024.04.021.

PMID: 39147428

2024 Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy.
Colton M, Purev E, Haverkos B, Bair S, Jasem J, Jacob A, **Kamdar M**. (Senior author)
Clin Lymphoma Myeloma Leuk. 2024 Jun 26:S2152-2650(24)00240-4. doi: 10.1016/j.clml.2024.06.006.
PMID: 39034202

2024 Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on behalf of The American Society of Transplantation and Cellular Therapy and the European Society of Blood and Marrow Transplantation.
Iqbal M, **Kamdar M**, Kharfan-Dabaja MA et al
Transplant Cell Ther. 2024 Jul 5:S2666-6367(24)00487-1. PMID: 38972511

2024 Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
Morschhauser, **Kamdar M**, Nastoupil et al
Nat Med. 2024 Jun 3. doi: 10.1038/s41591-024-02986-9. PMID: 38830991

2024 Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.

Abramson JS, **Kamdar M** et al
Future Oncol. 2024 Mar 28. doi: 10.2217/fon-2023-0898. PMID: 38547003

2024 Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy.
Crombie JL, Graff T, **Kamdar M**, Dickinson M et al.
Blood. 2024 Jan 22:blood.2023022432. doi: 10.1182/blood.2023022432. PMID: 38252906

2023 Front-line Chemo-immunotherapy with Nivolumab and Dose-Adjusted EPOCH in Peripheral T-cell Lymphoma: A Phase I Trial.
Haverkos BM, **Kamdar M**, Porcu P et al
Blood Adv. 2023. doi: 10.1182/bloodadvances. PMID: 38150586

2023 Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium.
Vose JM, **Kamdar M**, Bi C et al; North American Mantle Cell Lymphoma Consortium.
J Hematol Oncol. 2023 Dec 16;16(1):122. doi: 10.1186/s13045-023-01520-7. PMID: 3810409

2023 Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
Budde LE, **Kamdar M**, Chavez JC et al.
Nat Med. 2023 Dec 10. doi: 10.1038/s41591-023-02726-5. PMID: 38072960

2023 Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma (MCL): Primary Analysis of the MCL Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.
Wang M, **Kamdar M**, Palomba ML et al
J Clin Oncol. 2023 Dec 10: doi: 10.1200/JCO.23.02214. PMID: 38072625

2023 Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas.

Major A, **Kamdar M.** (Senior author)

Hematology Am Soc Hematol Educ Program. 2023 doi: 10.1182/hematology.2023000438.

PMID: 38066907

2023 Impact of Cumulative Dose of Brentuximab Vedotin on Outcomes of Frontline Therapy for Advanced Stage Hodgkin Lymphoma.

Steiner RE, Bair SM, **Kamdar M**, Lee HJ et al.

Blood Adv. 2023 Aug 21: doi: 10.1182/bloodadvances.2023010700. PMID: 37603594

2023 Embracing chimeric antigen receptors for relapsed chronic lymphocytic leukaemia.

Kamdar M.

Lancet. 2023 Aug 19;402(10402):590-592. doi: 10.1016/S0140-6736(23)01611-2.PMID: 37597880

2023 Cellular therapy in lymphoma.

Sureda A, **Kamdar M**, Jacobson C. et al

Hematol Oncol. 2023 Jun 29. doi: 10.1002/hon.3200. PMID: 37382086

2023 Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma.

Duarte C, **Kamdar M.**

Am Soc Clin Oncol Educ Book. 2023 Jan;43:e390802. doi: 10.1200/EDBK_390802.PMID: 37098236

2023 Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions.

Major A, **Kamdar M**, Kline, J et al

Blood Adv. 2023 Apr 7:bloodadvances.2023010016. doi: 10.1182/bloodadvances.2023010016

2023 High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.

Zayac AS, **Kamdar M**, Olszewski AJ et al.

Blood Adv. 2023 May 12:bloodadvances.2023009731. doi: 10.1182/bloodadvances.2023009731

2023 Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes.

Wagner CB, **Kamdar M**, Shah H et al.

Haematologica. 2023 Apr 27. doi: 10.3324/haematol.2023.282780. PMID: 37102592

2023 A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.

Dawson MA, **Kamdar M**, Dickinson M et al

Clin Cancer Res. 2023 Feb 16;29(4):711-722. doi: 10.1158/1078-0432.CCR-22-1284.PMID: 36350312

2023 A Multicenter Analysis of the Outcomes with Venetoclax in Patients with Relapsed Mantle Cell Lymphoma.

Sawalha Y, Cohen JB, **Kamdar M**, Hill, B et al

Blood Adv. 2023 Feb 21:bloodadvances.2022008916. doi: 10.1182/bloodadvances.2022008916. Online ahead of print. PMID: 36809796

2023 A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma.

Shouse G, Kaempf A, Smilnak and **Kamdar M** et al

Blood Adv. 2023 Feb 3:bloodadvances.2022009309. doi: 10.1182/bloodadvances.2022009309. Online ahead of print. PMID: 36735393

2023 A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma

M J Cortese, **Kamdar M**, Hill, B et al

Leuk Lymphoma. 2022 Nov 2;1-12. doi: 10.1080/10428194.2022.2140281

2023 Clinical and radiographic predictors of progression and survival in relapsed/refractory lymphoma patients receiving anti-CD19 CAR T-cell therapy

Jodon, G, Colton, M and **Kamdar M** et al

Clin Lymphoma Myeloma Leuk;2022 Oct;22; <https://doi.org/10.1016/j.clml.2022.09.009>

2022 Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study

JS Abramson, **Kamdar M** et al

Blood.2022018730. <https://doi.org/10.1182/blood.2022018730>

2022 Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL

JS Abramson, **Kamdar M**, SR Solomon et al

Blood Adv. 2022 Dec 13;6(23):5969-5979. doi: 10.1182/bloodadvances.2022008106

2022 ABCLL-455 Multicenter retrospective analysis of single route prophylaxis in aggressive B-cell lymphomas. Orellana-Noia V, **Kamdar M**, Portell, C et al;Clin Lymphoma Myeloma Leuk;2022 Oct;22 Suppl 2:S381. doi: 10.1016/S2152-2650(22)01543-9.

2022 Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Abramson, J, Kamdar M, Solomon, S et al. Blood Adv. 2022 Sep 23;bloodadvances.2022008106. doi: 10.1182/bloodadvances.2022008106

2022 Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.

Thompson MC, **Kamdar M**, Mato AR et al.

Blood Adv. 2022 Jun 23:bloodadvances.2022007812. doi: 10.1182/bloodadvances.2022007812.

2022 Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Kamdar M, Solomon, S, Abramson, J et al

Lancet 2022 VOLUME 399, ISSUE 10343, P2294-2308, JUNE 18, 2022, [https://doi.org/10.1016/S0140-6736\(22\)00662-6](https://doi.org/10.1016/S0140-6736(22)00662-6)

2022 A cauldron of choices

Kamdar M. Blood, 2022 May 26;139(21):3103-3104.doi: 10.1182/blood.2022015995.

2022 21q22 amplification detection in three patients with acute myeloid leukemia: cytogenomic profiling and literature review.

Kudalkar EM, **Kamdar M**, Bao L et al.

Mol Cytogenet. 2022 Jul 7;15(1):30. doi: 10.1186/s13039-022-00606-0.

2022 A Multicenter Retrospective Study of Polatuzumab Vedotin in Patients with Large B-cell Lymphoma after CAR T-cell Therapy

Gouni S, **Kamdar M**, Strati P et al

Blood Adv. 2022 Mar 3:bloodadvances.2021006801. doi:10.1182/bloodadvances.2021006801.

2022 An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma

Aleruccio JP, **Kamdar M**, Lossos, IS et al

Blood Adv. 2022 Feb 23:bloodadvances.2021006844. doi:10.1182/bloodadvances.2021006844

2022 Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Sharman J, **Kamdar M**, Byrd JC et al

Leukemia 2022 Jan 1. doi: 10.1038/s41375-021-01485

2021 HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.

Alderuccio JP, **Kamdar M**, Cwynarski K et al

Blood Adv. 2021 Jul 27;5(14):2852-2862. doi: 10.1182/bloodadvances.2021004458.

2021 Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Orellana-Noia V, **Kamdar M**, Portell, C et al

Blood.2021012888. doi: 10.1182/blood.2021012888.

2021 COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.

Roeker LE, **Kamdar M**, Mato AR et al

Blood. 2021 Jul 23:blood.2021011841. doi: 10.1182/blood.2021011841.

2021 ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma

Munshi P, Hamadani M, **Kamdar M**, Fenske T et al

DOI: 10.1038/s41409-021-01288-9

2021 Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia.

Samuels C, **Kamdar M**.

Cancer Rep. 2021 Jul 12:e1505. doi: 10.1002/cnr2.1505.

2021 Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study

Zayac A, Evens, A, **Kamdar M**, Olszewski A et al
Hematologica. 2021 Feb 4.doi: 10.3324/haematol.2020.270876.

2021 Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers.

Evens AM, Danilov AV, Jagadeesh D, **Kamdar M**, Alderuccio, JP et al
Blood. 2020 Jul 14:blood.2020006926. doi: 10.1182/blood.2020006926.

2021 Burkitt Lymphoma International Prognostic Index

Olszewski AJ, Jakobsen, LH, **Kamdar M**, Even AM et al
J Clin Oncol. 2021 Jan 27:JCO2003288. doi: 10.1200/JCO.20.03288.

2020 Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

Pasquini MC, Hu ZH, **Kamdar M**, Grupp, S et al
Blood Adv. 2020 Nov 10;4(21):5414-5424. doi: 10.1182/bloodadvances.2020003092.

2020 Outcomes of COVID-19 in Patients with CLL: A Multicenter, International Experience.

Mato AR, Roeker LE, **Kamdar M**, Eyre TA et al
Blood. 2020 Jul 20:blood.2020006965. doi: 10.1182/blood.2020006965.

2020 How disease stage impacts the rate of second primary malignancies in patients with diffuse large B-cell lymphoma. **Kamdar M**. Clin Adv Hematol Oncol. 2020 Mar;18(3):147-149.

2020 Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab. Amaya ML, Jimeno A, **Kamdar M**. Drugs Today (Barc). 2020 Apr;56(4):287-294. doi: 10.1358/dot.2020.56.4.3127026.

2020 Acalabrutinib With or Without Obinutuzumab Versus Chlorambucil and Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukaemia: The Randomised, Controlled, Phase 3 ELEVATE TN Trial.

Sharman Jeff, MD, **Kamdar M**, Byrd John et al.
Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2.

2019 Evaluating Novel PET-CT Functional Parameters TLG and TMTV in Differentiating Low-grade Versus Grade 3A Follicular Lymphoma

Ajay Major MD, Andrew Hammes,MS, **Kamdar M**
Clinical lymphoma myeloma leukemia, 2020 Jan;20(1):39-46.
doi: 10.1016/j.clml.2019.09.609.

2019 Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Sehn LH, Herrera AF, Flowers CR, **Kamdar M**, Matasar MJ et al
J Clin Oncol. 2019 Nov 6:JCO1900172. doi: 10.1200/JCO.19.00172.

Manali Kamdar, MD

Mail Stop F754 1665 Aurora Court Aurora, Colorado 80045

720-848-0752 (O); 720-848-1786 (F)

manali.kamdar@ucdenver.edu

2019 Five-Year Outcomes of S1106 study of R-HCVAD Vs R-Bendamustine In Transplant Eligible Patients with Mantle Cell Lymphoma

Kamdar M, Jonathan W. Friedberg, MD and Sonali M. Smith, MD et al. Blood advances 2019 Oct 22;3(20):3132-3135. doi: 10.1182/bloodadvances.2019000526

2019 Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis.

Major A, Smith DE, Ghosh D, Rabinovitch R, **Kamdar M**. Cancer. 2019 Sep 11. doi: 10.1002/cncr.32513.

2018 Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis

AMajor, **Kamdar M**, RRabinovitch
Leukemia Lymphoma: 2018 Dec 3:1-10. doi: 10.1080/10428194.2018.1522435

2018 Positron Emission Tomography-based Analysis Can Accurately Predict Bone Marrow Involvement With Mantle Cell Lymphoma.

Morgan R, **Kamdar M**
Clin Lymphoma Myeloma Leuk. 2018. S2152-2650(18)30393-8. doi:10.1016/j.clml.2018.06.024.

2018 Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder

Major A, **Kamdar M**
Curr Treat Options Oncol. 2018 May 24;19(7):33. doi: 10.1007/s11864-018-0549-6

2018 Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning

Sharma P, Polleyea D, Smith CA, Purev E, **Kamdar M**, Gutman JA
Biol Blood Marrow Transplant. 2018 Aug;24(8):1671-1677. doi: 10.1016/j.bbmt.2018.04.019.

2017 PD-1 Blockade in mediastinal gray zone lymphoma

Melani C, Major A, Wilson W, **Kamdar M**
New England Journal of Medicine 2017 Jul 6;377(1):89-91. doi: 10.1056/NEJMc1704767

2017 PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD

Haverkos BM, Abbott,D, Hamadani M, **Kamdar M**, Gutman J, Devine SM
Blood. 2017 May 3: blood-2017-01-761346. doi: 10.1182/blood-2017-01-761346

2017 Marginal Zone Lymphoma: no longer just a side kick

Kamdar M, Smith S
Journal of clinical Oncology/2017 Apr 27:JCO2017722835.
doi: 10.1200/JCO.2017.72.2835

2017 Secondary CNS Involvement of ALK-Negative Anaplastic Large Cell Lymphoma.

Major A, Pan Z, **Kamdar M**
Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24733.

2016 Improved Survival with Combined Modality Therapy in the Modern Era for Primary Mediastinal B-Cell Lymphoma

Jackson MW, Rusthoven CG, **Kamdar M**, Rabinovitch R
Am J Hematol. 2016 Feb 6. doi: 10.1002/ajh.24325

2015 Improved Survival with Radiotherapy in Stage I-II Primary Mediastinal B-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis

Jackson MW, Rusthoven CG, **Kamdar M**, Rabinovitch R
*International Journal of Radiation Oncology*Biology*Physics.* 2015 Sep 25.
doi:10.1016/j.ijrobp.2015.09.017

Editorial/ Consensus Guidelines White Papers

Editorials

2024 CARs to the rescue: rare aggressive lymphoma gets a power up.

Kamdar M.

Blood Adv. 2024 Oct 22;8(20):5342-5343. doi: 10.1182/bloodadvances.2024014118.
PMID: 3939264

2024 Addressing Unmet Needs in Large B-Cell Lymphoma With Allogeneic CAR T-Cell Therapy

Kamdar M, Connor ,M

ASCO daily news: May 2024; <https://dailynews.ascopubs.org/do/addressing-unmet-needs-large-b-cell-lymphoma-allogeneic-car-t-cell-therapy>

2023 Embracing chimeric antigen receptors for relapsed chronic lymphocytic leukaemia.

Kamdar M.

Lancet. 2023 Aug 19;402(10402):590-592. doi: 10.1016/S0140-6736(23)01611-2.PMID: 37597880

2022 A cauldron of choices

Kamdar M.

Blood, 2022 May 26;139(21):3103-3104.doi: 10.1182/blood.2022015995.

2020 How disease stage impacts the rate of second primary malignancies in patients with diffuse large B-cell lymphoma.

Kamdar M.

Clin Adv Hematology Oncology. 2020 Mar;18(3):147-149.PMID: 32609662

2017 Marginal Zone Lymphoma: no longer just a side kick

Kamdar M, Smith S

Journal of clinical Oncology/2017 Apr 27:JCO2017722835. doi: 10.1200/JCO.2017.72.2835

2024 Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on behalf of The American Society of Transplantation and Cellular Therapy and the European Society of Blood and Marrow Transplantation.
Iqbal M, **Kamdar M**, Kharfan-Dabaja MA et al
Transplant Cell Ther. 2024 Jul 5:S2666-6367(24)00487-1.

2024 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Wierda WG, Brown J, Abramson JS, **Kamdar M**, Kipps TJ, et al.
J Natl Compr Canc Netw. 2024 Apr;22(3):175-204. doi: 10.6004/jnccn.2024.0018.

2024 Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy.
Crombie JL, Graff T, **Kamdar M**, Dickinson M et al.
Blood. 2024 Jan 22:blood.2023022432. doi: 10.1182/blood.2023022432.

2021 ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma
Munshi P, Hamadani M, **Kamdar M**, Fenske T et al
DOI: 10.1038/s41409-021-01288-9

Book Chapters

2025 High grade lymphoid malignancies in Abeloff's Clinical Oncology (Chapter in review)

2023 Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas.
Major A, **Kamdar M**.

Hematology American Society of Hematology Education Program

2023 Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma.

Duarte C, **Kamdar M**.

American Society of Clinical Oncology Education Book

2014 Chapters: 1. Sirolimus as GVHD prophylaxis 2. HLA

Publication: Guide to clinical hematopoietic cell grafting (The Stanford Red Book)

Supervisor: Dr. Jonathan Benjamin

Editorial Boards/Data safety monitoring committee (DSMC) Member

2025 Steering Committee Co-chair for AstraZeneca CHORUS Hematology Program, which will focus on DLBCL in North America and South America

2025 Scientific Steering Committee Member for Lyell Immunotherapy PiNACLE-H2H Pivotal trial

2025 Editorial Board Member for VJHemOnc

2022-current Review Editor for Frontiers in Hematology

2021-current Editorial committee member for LRF's disease and treatment specific patient publication

2020-2025 DSMC member for clinical protocol – “Magnify: Phase 3b Study of Lenalidomide + Rituximab (R²) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma”

2021-current DSMC member for clinical protocol “CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy.

2018-current Editorial Board, *Clinical Lymphoma, Myeloma and Leukemia*

2016 Associate Editor: Practical medical education and science

Scientific Abstracts (Oral and Poster Presentations)

2025 INSIGHT: A baseline laboratory profile independently predicts outcomes and demonstrates superiority of lisocabtagene maraleucel (iso-cel) over standard of care (SOC) in second-line (2L) large B-cell lymphoma (LBCL) regardless of baseline profile

Kamdar M, Ansari S et al

ASH 2025, Poster presentation, Paper number 1775

2025 Lisocabtagene maraleucel (iso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

Kamdar M, Abramson J et al

ASH 2025, Poster Presentation, Paper number 3710

2025 Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study

Kamdar M, Budde E et al

ASH 2025, Oral Presentation, Paper number 3735

2025 Patient-reported outcomes (PROs) with lisocabtagene maraleucel (iso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study

Karmali R, **Kamdar M**, Palomba M et al

ASH 2025 Oral abstract, Paper number 709

2025 Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Huang J, **Kamdar M**, Shadman M et al

ASH 2025, Oral Abstract, Paper number 798

2025 Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis

Xi, Yang, **Kamdar M**, Karimi Y et al

ASH 2025, Oral Abstract, Paper number 783

2025 Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (iso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Ahmed S, **Kamdar M**, Morschhauser F et al

ASH 2025, Oral Abstract, Paper number 467

2025 Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma

Chohan K, **Kamdar M**, Ahmed S et al

ASH 2025, Poster presentation, Paper number 5520

2025 Safety and efficacy of MT-601 in relapsed or refractory (r/r) Hodgkin lymphoma

Abdelhakim H, **Kamdar M**, et al

ASH 2025, Poster presentation, Paper number 1846

2025 MT-601 demonstrates favorable safety and durable responses in relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL)

Shouse G, **Kamdar M** et al

ASH 2025, Poster Presentation, Paper number 5944

2025 Fixed-duration outpatient subcutaneous mosunetuzumab + polatuzumab vedotin shows robust efficacy in a Phase II study of relapsed/refractory post-BTKi mantle cell lymphoma

Budde E, **KamdarM** (Co-first author), WangM et al- Paper no- 050, Oral presentation, International Conference of Malignant Lymphoma, Lugano, 2025

2025 Lisocabtagene maraleucel (lisocel) in patients (pts) with relapsed or refractory (R/R) marginal zone lymphoma (MZL) in the phase 2 TRANSCEND FL study

PalombaL, **KamdarM**, MorschhauserF et al- Paper no- 055, Oral presentation, International Conference of Malignant Lymphoma, Lugano, 2025

2025 Optimizing post—chimeric antigen receptor T cell monitoring: evidence across lisocabtagene maraleucel pivotal clinical trials and real-world experience

KamdarM et al, Paper no- 7026, Poster presentation ASCO 2025 and ICML 2025

2024 Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (lisocel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Alizadeh A, **KamdarM** et al; Paper No: 72, Oral presentation ASH 2024

2024 Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis

Zachary D. Epstein-Peterson, **KamdarM** et al; Paper no: 238, Oral Presentation ASH 2024

2024 Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Juan Aldurechhio, **KamdarM**; Paper No: 571, oral presentation Ash 2024

2024 Preliminary Safety and Tolerability of CD19x22 CAR-T Cell Therapy in Adolescent and Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

KamdarM et al, Paper No: 4510; Poster presentation, ASH 2024

Manali Kamdar, MD

720-848-0752 (O); 720-848-1786 (F)

Mail Stop F754, Rm 4323, 1665 Aurora Court Aurora, Colorado 80045

manali.kamdar@cuanschutz.edu

2024 Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): 3- yr follow up from the Phase 3 Transform Study

KamdarM, SSolomon, JAbramson et al: ASCO 2024: Oral Abstract 7013

2024 Lisocabtagene Maraleucel (liso-cel), in patients with R/R Mantle cell lymphoma: subgroup analyses by number of prior lines of therapy and response to prior BTK inhibitors (TRANSCEND -MCL) MPalomba, **KamdarM**, MWang et al: ASCO 2024: Oral abstract 7016

2023 Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study LStepan, AA Alizadeh, **KamdarM** et al ASH 2023, Abstract 225, Oral Presentation

2023 Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study

ML Wang, **KamdarM**, EBudde et al, Abstract 734 Oral Presentation ASH 2023

2023 TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma Morschhauser, **KamdarM**, LNastoupil et al, Abstract 602, Oral Presentation, ASH 2023

2023 Key Findings from a Transformative Quality Improvement Initiative on Advancing CAR T-Cell Treatment in Non-Hodgkin Lymphoma **KamdarM**, Ellie Moses-Okwei, et al Abstract 3705, Poster Presentation, ASH 2023

2022 Feasibility and safety of a novel CD19 CAR T cell therapy in adults with R/R B-NHL **KamdarM**, MVerneris et al; ASH 2022 Poster CT522

2021-22 Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study **KamdarM**, SSolomon, JAbramson et al: ASH 2021: Oral Abstract 91 and TCT 2022: Oral Abstract

2021 Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Favorable Safety Profile in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: Updated Results from a Phase Ib/II Study

EBudde, **KamdarM**, JChavez et al: ASH 2021: Oral Abstract 533

2021 High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers

AZayac, **KamdarM**, AOlszewksi et al: ASH 2021: Oral Abstract 455

2021. Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study GShouse, **KamdarM**, ADanilov et al: ASH 2021: Oral Abstract 529

2021 A Pilot Study Using Nivolumab in Combination with Standard of Care Chemotherapy in Newly Diagnosed Peripheral T-Cell Lymphomas

BHaverkos, **KamdarM**, PPorcu et al: ASH 2021: Poster 2444

2021 A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy

SGouni, **KamdarM**, PStrati et al: ASH 2021: Poster 2495

2021 Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax

MThompson, **KamdarM**, Amato et al: ASH 2021: Poster 2628

2021 Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study

JAbramson, SSoloman, **KamdarM** et al: ASH 2021: Poster 3845

2021 Clinical and Radiographic Predictors of Progression and Survival in Relapsed/Refractory Lymphoma Patients Receiving CAR-T Cell Therapy

GJodon, RMorgan, **KamdarM** et al: ASH 2021: Poster 3879

2021 Acalabrutinib \pm obinutuzumab versus obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: Elevate-TN four-year follow up.

JSharman, **KamdarM**, JByrd et al: ASCO 2021: Poster Abstract 7509

2021 Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin's lymphoma (B-NHL)

EBudde, NGhosh, **KamdarM**, CDiefenbach et al: ASCO 2021: Poster Abstract 7520

2021 Experience of Prior Anti-CD19 Therapy in Patients With Relapsed or Refractory Large B-Cell Non-Hodgkin Lymphoma Receiving Lisocabtagene Maraleucel (liso-cel), an Investigational Anti-CD19 Chimeric Antigen Receptor T Cell Product

SSolomon, **KamdarM**, ML Palomba et al, TCT 2021: Poster Abstract

2020 Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

ML Palomba, LGordon, **KamdarM**, MWang et al, ASH 2020: Oral Abstract 118

2020 CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

VOrellans-Noia, DReed, **KamdarM**, CPortell et al; ASH 2020: Oral Abstract 478

2020 The Burkitt Lymphoma International Prognostic Index (BL-IPI)

AOlszewski, LJakobsen, **KamdarM**, AEvens et al; ASH 2020: Oral Abstract 705

2020 Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis

JAldeucci, AOlszewski, **KamdarM**, KCwynarski et al; ASH 2020: Oral abstract 706

2020 Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis

YSawalha, SGoyal, **KamdarM**, JCohen et al; ASH 2020: Poster 2953

2020 Worldwide Examination of Patients with CLL Hospitalized for COVID-19

LRoeker, LScarfo, **KamdarM**, AMato et al; ASH 2020: Poster 1590

2020 Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma

MSohail, HLi, **KamdarM**, BHill et al; ASH 2020: Poster 1218

2020 Real World Outcomes of Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy: An Updated Analysis

LFitzgerald, AKittai, **KamdarM**, BHu et al; ASH 2020: Poster 3038

2020 A Multi-Center Analysis of the Impact of Dose Level of R-EPOCH on Outcomes of Patients with Double/Triple-Hit B-Cell Lymphoma

MCortese, WWei, **KamdarM**, BHill et al; ASH 2020: Poster 2126

2020 Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen

MThompson, JAllan, **KamdarM**, AMato et al; ASH 2020: Poster 3136

2020 Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis

JAldeucci, ABeaven, **KamdarM**, ILossos et al; ASH 2020: Poster 2050

2020 Post-transplant lymphoproliferative disorder (PTLD) after solid organ transplant (SOT): A multicenter real world analysis (RWA) of 877 patients (pts) treated in the modern era.

DJagadeesh, DTsai, **KamdarM** et al; ASCO 2020: 10.1200/JCO.2020.38.15_suppl.e20026

2020 Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.

LFitzgerald, BHu, **KamdarM** et al; ASCO 2020: 10.1200/JCO.2020.38.15_suppl.803

2019 The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)

AEvens, **KamdarM**, AOlszewski et al, ASH 2019: Oral Abstract 397

2019 Dose Reduction or Omission of Vinca Alkaloids during Initial Chemotherapy Treatment Does Not Impact Outcomes in Patients with Lymphoma

NMistry, DAbbott, **KamdarM** ASH 2019: Poster 4126

2019 Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis
AEvens, **KamdarM**, AOlszewski et al; ASH 2019: Oral Abstract 402

2019 ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
JSharman, WWierda, SCoutre, **KamdarM**, JWoyach et al; ASH 2019: Oral abstract 31

2019 Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry
SJaglowski, Zhu, **KamdarM** et al ASH 2019: Oral abstract 766

2018 Polatuzumab vedotin with bendamustine and rituximab/ obinutuzumab in relapsed/refractory DLBCL: Updates results of a Phase Ib/II Study
LSehn, **KamdarM**, Ahererra, GKu, MMatasar
American society of clinical oncology- Oral Abstract 7507; ASH 2018- Abstract 1683

2018 Addition of rituximab to high-dose methotrexate regimens improves complete response rates and median overall survival in non-germinal center primary CNS lymphoma
NMistry, **KamdarM**, DNey; ASH 2018- Abstract 4217

2018 Outcomes of follicular lymphoma patients treated with frontline bendamustine rituximab: impact of histologic grade and early progression on overall survival.
AWinter, LNastoupil, **KamdarM**, BHill; ASH 2018- Abstract 4146

2018 Chronic graft versus host disease burden and relapse rates are lower with comparable overall survival and graft versus host disease free, relapse free survival following adult umbilical cord transplantation.

PSharma, **KamdarM**, JGutman; ASH 2018- Abstarct 4660

2018 Baseline PET-CT functional parameters to identify low-grade versus grade 3A Follicular Lymphoma
AMajor, AHammer, RMorgan, **KamdarM**
American society of clinical oncology-Abstract e19541

2018 Risks and types of secondary primary malignancies in DLBCL survivors changes over time based on stage at diagnosis
AMajor, DSmith, DGhosh, RRabinovitch, **KamdarM**
American Society of clinical oncology- Abstract e19540

2018 Cardiac assessment within 5 years of lymphoma treatment can detect patients with high risk of cardiotoxicity and undiagnosed coronary artery disease
NMistry, DSmith, LKondapalli, DGhosh, **KamdarM**
American society of clinical oncology- Abstract e19562

2018 A phase 1 study of ALX148, a CD47 blocker, alone and in combination with antibodies in patients with advanced malignancy and non-hodgkin Lymphoma

NLakhani, **KamdarM**, WMessersmith

American society of clinical oncology- Poster Abstract 3068; ASH 2020 Poster 3016

2018 Multi-center retrospective study evaluating outcomes of grade 3 A follicular lymphoma

KGreene, TPhillips, ADanilov, **KamdarM**, DStephens

American society of clinical oncology- Poster Abstract 7551

2018 Long term follow up of S1106: Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma

KamdarM, RChen, JFriedberg, SSmith

LRF Mantle cell lymphoma workshop- Session VI MCL

ASH 2018- Abstract Poster 1593

2018 Phase 1 study of Molibresib, a selective bromodomain and extra terminal protein inhibitor: Results from part 1 of Phase I/II open label single agent study in patients with hematologic malignancies

MDickinson, **KamdarM**, ADhar

ASH 2018- Abstract 1682

2017 Addition of Polatuzumab vedotin to bendamustine and rituximab improves outcomes in transplant ineligible patients with relapsed refractory diffuse large B cell lymphoma versus BR alone: results from a randomized phase 2 study

LSehn, **KamdarM**, CFlowers; ASH 2017- Poster Presentation, Abstract 2821

2017 Administration of Plerixafor for peripheral blood CD34+ stem cell content of less than 30 x 10^6/L for autologous stem cell mobilization leads to decreased apheresis days and increased total yield

KamdarM, CSmith; EBMT- Poster Presentation, Abstract A091

2017 Polatuzumab Vedotin combined with bendamustine and rituximab or obinutuzumab in patients with relapsed or refractory follicular lymphoma or diffuse large b cell lymphoma

AHerrera, M,Matasar,**KamdarM**, LSehn

American Society of Hematology- Abstract 4194

14th ICML Conference- Lugano- Abstract 284

EHA 2017 (Updated results) – Oral presentation- Abstract S468

2016 Checkpoint blockade for treatment of relapsed lymphoma following allogeneic Hematopoietic cell transplant: use may be complicated by onset of severe acute graft versus host disease

BHaverkos, **KamdarM**, SDevine; American Society of Hematology- Abstract 1163

2016 Presenting characteristics and Treatment selection for elderly patients with Classical Hodgkin Lymphoma

MWJackson, **KamdarM**, RRabinovitch

Pan Pacific Lymphoma conference -Poster Presentation

Manali Kamdar, MD

Mail Stop F754 1665 Aurora Court Aurora, Colorado 80045

720-848-0752 (O); 720-848-1786 (F)

manali.kamdar@ucdenver.edu

2016 Post transplant diffuse large B cell lymphoma with non germinal center B-cell subtype frequently lacks programmed cell death ligand (PD-L1) overexpression which may influence overall outcomes

ZNooruddin, KamdarM

ASH meeting on Lymphoma- Abstract 90, ASH 2016- Abstract 3054, Poster Presentation

2016 Final results of IHC analyses and Prognostic factors in post transplant lympho Proliferative disorders after solid organ transplantation: A single center Experience

ZNooruddin, KamdarM

European Hematology Association- Abstract EHA-3164

2016 Single Institution Retrospective Review of patients with Primary CNS lymphoma

AJohnson, KamdarM, DNey

American Society of Clinical Oncology- Abstract 165552

2015 IHC Analysis and Prognostic Factors in Post Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A single center experience

ZNooruddin, KamdarM; American Society of Hematology – Poster presentation; Abstract 1443

2014 Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained disease response and promising donor immune modulation:

CRyan, KamdarM, DMiklos

American Society of Hematology – Poster Presentation, Abstract 1186

2013 **An internist's perspective of acquired hemophilia**

American College of Physicians, NC Chapter, Poster

KamdarM

2013 KRAS gene mutation status in lung cancer affects sensitivity to pemetrexed: A retrospective analysis

J Clin Oncol 31,2013 (suppl;abstr e19154)

KamdarM, Teresa Parent, Paul R Walker

2012 Retrospective review of patients afflicted with TTP in East Carolina

KamdarM, DLiles

American Society of Hematology - Abstract 2200, Poster Presentation

2012 Phase II Trial with daily Pulse Interleukin-2 therapy in patients with Acute Myeloid Leukemia

PWalker, KamdarM, AAsch

J Clin Oncol 30, 2012 (suppl; abstr e17008)

2011 Sudden cardiac death in the sickle cell patient population

KamdarM, DLiles

American Society of Hematology - Abstract 1061, Poster Presentation

Manali Kamdar, MD

720-848-0752 (O); 720-848-1786 (F)

Mail Stop F754, Rm 4323, 1665 Aurora Court Aurora, Colorado 80045

manali.kamdar@cuanschutz.edu

2010 A retrospective review to evaluate the safety and survival of treatment of adults with newly diagnosed Glioblastoma Multiforme with surgery, Gliadel Wafers, radiation and concurrent Temozolomide followed by adjuvant Temozolomide

KamdarM, DThompson

American Association of Neurosurgeons Society - Abstract 64831, Poster Presentation

Professional Memberships/Societies

American Society for Blood and Marrow Transplantation

American Society of Hematology

American Society of Clinical Oncology

European Hematology Association